Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Danazol
Drug ID BADD_D00576
Description A synthetic steroid with antigonadotropic and anti-estrogenic activities that acts as an anterior pituitary suppressant by inhibiting the pituitary output of gonadotropins. It possesses some androgenic properties. Danazol has been used in the treatment of endometriosis and some benign breast disorders.
Indications and Usage For the treatment of endometriosis and fibrocystic breast disease (in patients unresponsive to simple measures). Also used for the prophylactic treatment of all types of hereditary angioedema in males and females.
Marketing Status Prescription; Discontinued
ATC Code G03XA01
DrugBank ID DB01406
KEGG ID D00289
MeSH ID D003613
PubChem ID 28417
TTD Drug ID D09IPV
NDC Product Code 0527-1392; 53104-7501; 49076-5201; 0527-1369; 71052-662; 62991-2832; 42291-243; 0555-0635; 0555-0633; 38779-0174; 49452-2436; 0555-0634; 0527-1368; 71205-861; 71205-862
Synonyms Danazol | Danazant | Panacrine | Danocrine | Ladogal | Cyclomen | Danatrol | Danol | Danoval | Norciden | Azol | Danazol-Ratiopharm | Danazol Ratiopharm
Chemical Information
Molecular Formula C22H27NO2
CAS Registry Number 17230-88-5
SMILES CC12CCC3C(C1CCC2(C#C)O)CCC4=CC5=C(CC34C)C=NO5
Chemical Structure
ADR Related Proteins Induced by Drug
ADR Term Protein Name UniProt AC TTD Target ID PMID
ThrombophlebitisProtein kinase C delta typeQ05655T448613840287; 2363094; 8800154; 2146406
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Paraesthesia17.02.06.005--
Peliosis hepatis09.01.07.010--Not Available
Pelvic pain21.10.01.001; 20.02.03.007; 07.01.06.012--
Petechiae24.07.06.004; 23.06.01.003; 01.01.03.002--Not Available
Photosensitivity reaction23.03.09.003--
Platelet count decreased13.01.04.0010.016230%
Pleuritic pain22.02.04.008--
Polycythaemia01.07.01.001--Not Available
Premature baby18.04.02.0010.010820%Not Available
Presyncope24.06.02.010; 17.02.05.009; 02.01.02.0070.010820%
Protein total abnormal13.09.01.008--Not Available
Pruritus23.03.12.001--
Purpura24.07.06.005; 23.06.01.004; 01.01.04.003--
Pyrexia08.05.02.0030.010820%
Rash23.03.13.001--Not Available
Rash maculo-papular23.03.13.004--
Rash papular23.03.13.017--Not Available
Rash vesicular23.03.13.009--Not Available
Red blood cell count increased13.01.05.008--Not Available
Seborrhoea23.02.07.001--Not Available
Seborrhoeic dermatitis23.03.04.018--Not Available
Seizure17.12.03.001--
Semen volume abnormal13.20.01.011--Not Available
Shock24.06.02.002--Not Available
Skin disorder23.03.03.0070.010820%Not Available
Sleep disorder19.02.04.001--Not Available
Spermatogenesis abnormal21.03.03.002--Not Available
Spermatozoa progressive motility abnormal13.20.01.003--Not Available
Stevens-Johnson syndrome23.03.01.007; 12.03.01.014; 11.07.01.005; 10.01.03.020--
Syncope24.06.02.012; 17.02.04.008; 02.01.02.0080.016230%
The 4th Page    First    Pre   4 5 6    Next   Last    Total 6 Pages